 SAN DIEGO LAVAL, Quebec--BUSINESS WIRE--- BLU ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of BELLUS Health Inc. NASDAQ: BLU filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between September 5, 2019 and July 5, 2020. BELLUS is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is being developed for the treatment of chronic cough and other afferent 